Medicare Drug Price Savings Varied, Offset By Part D Redesign

Negotiated drug prices under Medicare resulted in a variety of price reductions compared with their 2023 net prices, which included five drugs facing cuts in the 30% to 40% range and two drugs subject to no price cuts, health policy analysts say.

A Tuesday report in Health Affairs Forefront compared the Biden administration’s 10 lowered drug costs from the first cycle of the Medicare Drug Price Negotiation Program with their Part D net prices in 2023. The analysis comes after the Centers for Medicare & Medicaid Services in August touted billions of dollars in savings from the negotiated drugs prices, ...